HOUSTON, Jan 5/PRNewswire/ — Hybrid Medical is one of the leading supporters of Genomics Science Black Tie Ball to take place April 14 at the Hotel ZA ZA in Houston. Proceeds from the event will support Houston Symphony and American Cancer Soceity, to initiate the development and deployment of promising new Genomics Science and therapies to improve and save patient lives. The celebrity chairperson of The Genomics Science Black Tie Ball is Congress Women Shelia Jackson Lee.
“As a Biotech Engineering company, Hybrid Medical is honored to support The Genomics Science Black Tie Ball ,” says Robert Graham, Executive Vice President of Hybrid Medical North America. “It is only through the medical community and philanthropic outreach that we can complete our mission, which is putting into the hands of healthcare professionals the tools they need to treat breast cancer and to improve, prolong and save patient lives.”
The first and only freestanding Genomics Biotech Engineering center of its kind in Houston, The Hybrid Medical GenNxeix, is hosting the event, as well as serving as a major sponsor Lilly.
“Genomics Science Black Tie Ball was put together with the same principles for why we started Hybrid Medical on the most humanistic level,” says Rose Conrad., the Center’s Founder and CEO. “It is about giving back to people and the community, and bringing genomics cancer care to the next level. It is in harmony with Hybrid Medical’s philosophy, which emphasizes caring for the whole person, not just treating their disease. The most fundamental understanding of the preciousness of life is what has driven us to pursue our dream to help people with cancer–to help them live fuller lives while under our care and ideally once their disease is defeated.”
Houston Press
PERFORMANCES
Wednesday, November 30, 2011
Tuesday, November 22, 2011
Robert Graham Reports Ny Times Ferrari Club Of Houston Says President Obama We Want To Pay Our Share
Wednesday, November 16, 2011
The New Leading Technology To Cure Breast Cancer is Here Nanoparticles and Semiconductor
Houston, TX – November 17, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Medical Media
The New Leading Technology To Cure Breast Cancer is Here according to Rose Conrad Ph.D. CEO of Hybrid GenNxeix Inc Nanoparticles and Semi Conductors
Hybrid GenNxeix Conrad explains Quantum dots (QDs), also known as semiconducting nanoparticles, are promising zero‐dimensional advanced materials because of their nanoscale size and because they can be engineered to suit particular applications such as nonlinear optical devices (NLO), electro‐optical devices, and computing applications. QDs can be joined to polymers in order to produce nanocomposites which can be considered a scientific revolution of the 21st century. One of the fastest moving and most exciting interfaces of nanotechnology is the use of QDs in medicine, cell and molecular biology. Recent advances in nanomaterials have produced a new class of markers and probes by conjugating semiconductor QDs with biomolecules that have affinities for binding with selected biological structures. The nanoscale of QDs ensures that they do not scatter light at visible or longer wavelengths, which is important in order to minimize optical losses in practical applications. Moreover, at this scale, quantum confinement and surface effects become very important and therefore manipulation of the dot diameter or modification of its surface allows the properties of the dot to be controlled. Quantum confinement affects the absorption and emission of photons from the dot. Thus, the absorption edge of a material can be tuned by control of the particle size. Nanocomposite systems for nanomedicine and bioengineering applications
Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.
GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs
The New Leading Technology To Cure Breast Cancer is Here according to Rose Conrad Ph.D. CEO of Hybrid GenNxeix Inc Nanoparticles and Semi Conductors
Hybrid GenNxeix Conrad explains Quantum dots (QDs), also known as semiconducting nanoparticles, are promising zero‐dimensional advanced materials because of their nanoscale size and because they can be engineered to suit particular applications such as nonlinear optical devices (NLO), electro‐optical devices, and computing applications. QDs can be joined to polymers in order to produce nanocomposites which can be considered a scientific revolution of the 21st century. One of the fastest moving and most exciting interfaces of nanotechnology is the use of QDs in medicine, cell and molecular biology. Recent advances in nanomaterials have produced a new class of markers and probes by conjugating semiconductor QDs with biomolecules that have affinities for binding with selected biological structures. The nanoscale of QDs ensures that they do not scatter light at visible or longer wavelengths, which is important in order to minimize optical losses in practical applications. Moreover, at this scale, quantum confinement and surface effects become very important and therefore manipulation of the dot diameter or modification of its surface allows the properties of the dot to be controlled. Quantum confinement affects the absorption and emission of photons from the dot. Thus, the absorption edge of a material can be tuned by control of the particle size. Nanocomposite systems for nanomedicine and bioengineering applications
Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.
GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.
A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs
Thursday, November 3, 2011
There is A Tool That Calculates A Woman Risk of Developing Breast Cancer Within The Next Five Years
Houston, TX – November 03, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Medical Media:
President Obama IS Women with Breast Cancer Being Cheated
Your Breast Cancer diagnosis is just average number. Yes a Gail number
92% Of Oncologist use something called a Gail Model for Breast Cancer Diagnosis & Treatment. Genomics is 72 % more effective than the Gail Model
Women What Are We doing About a Cure for Breast Cancer Today. Genomic is The Next Generation to The Gail Model
Background:
The Breast Cancer Risk Assessment Tool (the Gail model) was designed by researchers at the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project as a tool for health care providers. The tool calculates a woman's risk of developing breast cancer within the next five years and within her lifetime (up to age 90). It takes into account seven key risk factors for breast cancer.
• Age
• Age at first period
• Age at the time of the birth of her first child (or has not given birth)
• Family history of breast cancer (mother, sister or daughter)
• Number of past breast biopsies
• Number of breast biopsies showing atypical hyperplasia
• Race/ethnicity
Hybrid GenNxeix Researchers notice that the Breast Cancer Risk Assessment Tool does not calculate individual breast cancer risk, but rather the average risk for a group of women with similar risk factors. Thus, it is not clear what this risk means for any one woman. Say the model gives you a five-year risk of 1.7 percent. This means the tool estimates that 1.7 percent of women who have risk factors similar to your own will develop breast cancer over the next five years.
Women who have a five-year risk of 1.67 percent or higher (of the risk of an average 60-year-old woman) are classified as "high-risk". This score (a five-year risk of 1.67 percent or higher) is the cut-off for the FDA guidelines on tamoxifen and raloxifene use for breast cancer risk reduction.
Targeted therapies are transforming the way people treat cancer. These carefully designed drugs have already begun to make Genomic personalized medicine a reality and will continue to help doctors tailor cancer treatment based on the characteristics of each individual's cancer. It is important that health care professionals become familiar with the concept of targeted therapies so they can communicate with their patients about these new approaches and help patients make better-informed treatment decisions.
Treatment for breast cancer depends on the stage of the disease, but often includes surgery, radiation therapy, and chemotherapy. Some targeted therapies, including antihormone therapies and Herceptin® (trastuzumab), have also become part of standard treatment for breast cancer when a patient's tumor expresses the targets of these drugs. Preclinical experiments and clinical trials are currently underway to evaluate additional targeted therapies a
Hybrid GenNxeix Chief Science Officer says 75% of breast tumors rely on estrogen. These tumors are referred to as "estrogen dependent." Tumors that do not rely on estrogen for growth are called "estrogen independent."
The epidermal growth factor receptor family consists of four cell surface receptors: EGF receptor, also called HER1; HER2/neu; HER3; and HER4. Binding of specific growth factors, or ligands, to three of these receptors causes them to interact, or dimerize, either with a receptor of the same type or with another family member. HER2 is called an "orphan receptor" because it does not interact directly with any ligand. Instead, it dimerizes with ligand-bound EGF receptor, HER3, or HER4.
Hybrid GenNxeix Chief Science Officer says 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
President Obama IS Women with Breast Cancer Being Cheated
Your Breast Cancer diagnosis is just average number. Yes a Gail number
92% Of Oncologist use something called a Gail Model for Breast Cancer Diagnosis & Treatment. Genomics is 72 % more effective than the Gail Model
Women What Are We doing About a Cure for Breast Cancer Today. Genomic is The Next Generation to The Gail Model
Background:
The Breast Cancer Risk Assessment Tool (the Gail model) was designed by researchers at the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project as a tool for health care providers. The tool calculates a woman's risk of developing breast cancer within the next five years and within her lifetime (up to age 90). It takes into account seven key risk factors for breast cancer.
• Age
• Age at first period
• Age at the time of the birth of her first child (or has not given birth)
• Family history of breast cancer (mother, sister or daughter)
• Number of past breast biopsies
• Number of breast biopsies showing atypical hyperplasia
• Race/ethnicity
Hybrid GenNxeix Researchers notice that the Breast Cancer Risk Assessment Tool does not calculate individual breast cancer risk, but rather the average risk for a group of women with similar risk factors. Thus, it is not clear what this risk means for any one woman. Say the model gives you a five-year risk of 1.7 percent. This means the tool estimates that 1.7 percent of women who have risk factors similar to your own will develop breast cancer over the next five years.
Women who have a five-year risk of 1.67 percent or higher (of the risk of an average 60-year-old woman) are classified as "high-risk". This score (a five-year risk of 1.67 percent or higher) is the cut-off for the FDA guidelines on tamoxifen and raloxifene use for breast cancer risk reduction.
Targeted therapies are transforming the way people treat cancer. These carefully designed drugs have already begun to make Genomic personalized medicine a reality and will continue to help doctors tailor cancer treatment based on the characteristics of each individual's cancer. It is important that health care professionals become familiar with the concept of targeted therapies so they can communicate with their patients about these new approaches and help patients make better-informed treatment decisions.
Treatment for breast cancer depends on the stage of the disease, but often includes surgery, radiation therapy, and chemotherapy. Some targeted therapies, including antihormone therapies and Herceptin® (trastuzumab), have also become part of standard treatment for breast cancer when a patient's tumor expresses the targets of these drugs. Preclinical experiments and clinical trials are currently underway to evaluate additional targeted therapies a
Hybrid GenNxeix Chief Science Officer says 75% of breast tumors rely on estrogen. These tumors are referred to as "estrogen dependent." Tumors that do not rely on estrogen for growth are called "estrogen independent."
The epidermal growth factor receptor family consists of four cell surface receptors: EGF receptor, also called HER1; HER2/neu; HER3; and HER4. Binding of specific growth factors, or ligands, to three of these receptors causes them to interact, or dimerize, either with a receptor of the same type or with another family member. HER2 is called an "orphan receptor" because it does not interact directly with any ligand. Instead, it dimerizes with ligand-bound EGF receptor, HER3, or HER4.
Hybrid GenNxeix Chief Science Officer says 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
Subscribe to:
Posts (Atom)